Objective:This study aimed to analyze the correlation between platelet (PLT) count and the modified Rankin scale (mRS) in patients with cerebral infarction (CI) at the later stage of rehabilitation, which can be used to guide the secondary prevention strategy of CI. Methods:A total of 180 CI patients were divided into three groups according to PLT count: low PLT group (<125×109/L), medium PLT group (126– 225×109/L) and high PLT group (>226×109/L). The mRS was evaluated after three months and one year, respectively, and the difference in long-term prognosis between groups was analyzed. The mRS is an ordered scale coded from 0 (no symptoms at all) through 5 (severe disability) 6 (death). Results:Finally, a total of 99 patients had complete data. The results of the multiple comparisons among the three groups were as follows: the analysis of variance of the mRS at three months after onset yielded F = 6.714 and P = 0.002, and the difference was statistically significant. The mRS was lowest in the medium PLT group (2.09±1.465), and neurological function recovery was the best. After one year, the mRS for the medium PLT group was the lowest (1.49±1.523), with F = 6.860 and P = 0.002. The repeated measures analysis of variance revealed that the effect of continuous rehabilitation was significant in the interval from three months to one year after onset (F = 35.528, P < 0.001). This was very significant, especially for patients taking aspirin (F = 50.908, P < 0.001). However, for patients who did not take aspirin, the effect of continuous rehabilitation was not obvious during the nine months, and the difference between the results of two mRS measurements was not statistically significant (F = 1.089, P = 0.308). Conclusions:Patients with a PLT count of 126– 225×109/L had the lowest mRS between three months and one year after onset, but had the best recovery of nerve function. Patients who persisted in taking aspirin continued to significantly recover during the 9-month period, from three months to one year after onset. Aspirin is not only a secondary preventive drug, but also an important drug to promote the rehabilitation of CI patients.

中文翻译：

---

血小板计数对脑梗死远期预后的影响。

目的：本研究旨在分析脑梗死（CI）患者康复后期血小板（PLT）计数与改良Rankin量表（mRS）的相关性，以指导CI的二级预防策略。 . 方法：180例CI患者根据PLT计数分为3组：低PLT组（<125×109/L）、中PLT组（126～225×109/L）和高PLT组（>226×109/L）。 109/升）。分别在3个月和1年后评估mRS，分析组间长期预后的差异。mRS 是一个从 0（完全没有症状）到 5（严重残疾）6（死亡）的有序量表。结果：最终共有99例患者获得完整数据。三组多重比较结果如下：发病后3个月mRS方差分析F=6.714，P=0.002，差异有统计学意义。中PLT组mRS最低（2.09±1.465），神经功能恢复最好。一年后，中 PLT 组的 mRS 最低（1.49±1.523），F = 6.860，P = 0.002。重复测量方差分析显示，在发病后3个月至1年期间持续康复效果显着（F=35.528，P<0.001）。这非常重要，特别是对于服用阿司匹林的患者（F = 50.908，P < 0.001）。但对于未服用阿司匹林的患者，连续康复9个月的效果并不明显，并且两次 mRS 测量结果之间的差异无统计学意义（F = 1.089，P = 0.308）。结论：PLT计数为126～225×109/L的患者在发病后3个月至1年内mRS最低，但神经功能恢复最好。坚持服用阿司匹林的患者在发病后 3 个月至 1 年的 9 个月期间继续显着康复。阿司匹林不仅是二级预防药物，也是促进CI患者康复的重要药物。坚持服用阿司匹林的患者在发病后 3 个月至 1 年的 9 个月期间继续显着康复。阿司匹林不仅是二级预防药物，也是促进CI患者康复的重要药物。坚持服用阿司匹林的患者在 9 个月期间持续显着恢复，从发病后的三个月到一年。阿司匹林不仅是二级预防药物，也是促进CI患者康复的重要药物。